 Idazoxan treatment progressive supranuclear palsy preliminary report norepinephrine neurotransmission motor performance investigational drug idazoxan IDA patients progressive supranuclear palsy PSP double-blind crossover protocol women men mean age years mean duration illness years advanced parkinsonian syndrome supranuclear ocular motor palsies poor responses drugs administration mg tid IDA total score motor subscale score United Parkinson Disease Rating Scale Features included mobility balance gait measures digital dexterity significant changes measure placebo administration Corticobulbar manifestations eye movements treatment Side effects IDA transient hypertension tachycardia action tremor flushing sweating none severe patient withdrew study attempted treatments PSP IDA first medication double-blind study aspects motor function